9 completed, 1 recruiting, 1 terminated, 1 unknown. 9 Phase 2, 3 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 6, Recruiting 1, Terminated 1, Unknown 1 |
| Phase 1 | 3 | Completed 3 |
| Phase 3 | 1 | Withdrawn 1 |
Follow Connect Biopharm LLC: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Rademikibart IV for Acute Asthma and COPD Exacerbation Rademikibart - Asthma Acute, COPD Exacerbation Acute | Phase 2 | Recruiting | Connect Biopharm LLC | 40 | 2026-08-21 | 2026-10-27 |
| Rademikibart Add-on Treatment of an Acute COPD Exacerbation (Seabreeze STAT COPD) Rademikibart in prefilled syringe, Matching placebo in prefilled syringe - COPD Acute Exacerbation | Phase 2 | Completed | Connect Biopharm LLC | 159 | 2025-08-12 | 2026-09-16 |
| Rademikibart Add-on Treatment of an Acute Asthma Exacerbation (Seabreeze STAT Asthma) Rademikibart in prefilled syringe, Matching placebo in prefilled syringe - Asthma Acute | Phase 2 | Completed | Connect Biopharm LLC | 160 | 2025-08-08 | 2026-09-16 |
| A Study to Evaluate the Pharmacokinetics Similarity of CBP-201 in Healthy Adult Chinese Subjects Test drug (T1): CBP-201 injection (pre-filled syringe, 150 mg/1 mL), Test drug (T2): CBP-201 injection (pre-filled syringe, 300 mg/2 mL), Reference drug (R): CBP-201 injection (vial, 150 mg/1 mL) - Healthy Adult Subjects | Phase 1 | Completed | Connect Biopharm LLC | 324 | 2023-07-18 | 2023-10-31 |
| A Study to Evaluate the Safety and Efficacy of CBP-201 in Chinese Adult Subjects With Moderate to Severe AD CBP-201 - Atopic Dermatitis | Phase 2 | Unknown | Connect Biopharm LLC | 360 | 2023-07-15 | 2023-12-11 |
| CBP-201 in Adolescent and Adult Patients With Moderate-to-severe Atopic Dermatitis CBP-201, Placebo - Atopic Dermatitis | Phase 3 | Withdrawn | Connect Biopharm LLC | 2022-12-01 | 2023-03-21 | |
| A Study On Human Mass Balance And Biotransformation CBP-307 - Healthy Adult Subjects | Phase 1 | Completed | Connect Biopharm LLC | 6 | 2021-09-04 | 2022-04-05 |
| A Study to Evaluate the Efficacy and Safety of CBP-201 in Moderate to Severe Atopic Dermatitis in China CBP-201, Placebo - Moderate-to-severe Atopic Dermatitis | Phase 2 | Completed | Connect Biopharm LLC | 330 | 2021-08-31 | 2024-05-01 |
| A Study to Evaluate CBP-201, Rademikibart, in Adult Patients With Chronic Rhinosinusitis With Nasal Polyps CBP-201, Placebo - Chronic Rhinosinusitis With Nasal Polyps | Phase 2 | Terminated | Connect Biopharm LLC | 40 | 2021-06-16 | 2023-10-17 |
| Efficacy and Safety of CBP-201 in Patients With Moderate to Severe Persistent Asthma With Type 2 Inflammation CBP-201, Placebo - Moderate to Severe Persistent Asthma | Phase 2 | Completed | Connect Biopharm LLC | 322 | 2021-05-11 | 2024-03-29 |
| A Study to Assess the Efficacy and Safety of CBP-201 in Adult Subjects With Moderate to Severe Atopic Dermatitis CBP-201, placebo - Moderate-to-severe Atopic Dermatitis | Phase 2 | Completed | Connect Biopharm LLC | 226 | 2020-07-17 | 2023-08-01 |
| A Study Assessing the Efficacy and Safety of CBP-307 in Subjects With Moderate to Severe Ulcerative Colitis (UC) Double-Blind 0.2mg CBP-307, Double-Blind Placebo, Open-label CBP-307 - Moderate to Severe Ulcerative Colitis | Phase 2 | Completed | Connect Biopharm LLC | 145 | 2019-02-27 | 2024-05-06 |
| Phase 1 Study Accessing the Safety and Tolerability of CBP-307 CBP-307, Placebo - Autoimmune Diseases | Phase 1 | Completed | Connect Biopharm LLC | 64 | 2014-11-01 | 2016-11-03 |
Asthma (2) · Dermatitis, Atopic (2) · Pulmonary Disease, Chronic Obstructive (2) · Autoimmune Diseases (1) · Eczema (1) · Hypersensitivity (1) · Pruritus (1)
Double-Blind Method (1) · Drug Evaluation (1)
China (8) · United States (7) · Australia (4) · Argentina (2) · Georgia (2) · Poland (2) · Serbia (2) · Ukraine (2) · United Kingdom (2) · Hungary (1) · New Zealand (1) · Pakistan (1) · South Korea (1) · Spain (1)
Suzhou Connect (9) · Jason Lickliter, MD, PhD, FRACP (1) · Zheng Wei, PhD (1)